Long-Acting Calcium Channel Blockers for Hypertension
Long-acting dihydropyridine calcium channel blockers (CCBs), specifically amlodipine, are the primary CCBs recommended for hypertension treatment, with other options including felodipine, lercanidipine, and lacidipine.
Recommended Long-Acting CCBs
The evidence consistently identifies long-acting dihydropyridine CCBs as first-line agents for hypertension across multiple international guidelines 1, 2, 3, 4:
Dihydropyridine CCBs (Long-Acting):
- Amlodipine - Most widely studied and recommended; 5-10 mg once daily 5, 6
- Felodipine - 5-10 mg once daily 5
- Lercanidipine - Third-generation agent with improved tolerability profile 7, 8
- Lacidipine - Newer long-acting agent 8
Non-Dihydropyridine CCBs (for specific situations):
- Diltiazem (slow-release formulation) - 120-360 mg once daily 5
- Verapamil (slow-release formulation) - 120-480 mg once daily 5
Clinical Positioning
First-line monotherapy: Long-acting dihydropyridine CCBs are recommended as initial therapy for both diastolic/systolic hypertension and isolated systolic hypertension 1, 2, 3. The Canadian guidelines specifically recommend them with Grade A evidence for isolated systolic hypertension 1, 2.
Combination therapy: When used in combinations, long-acting dihydropyridine CCBs pair well with:
- ACE inhibitors or ARBs (Grade C evidence) 1, 3
- Thiazide/thiazide-like diuretics (Grade B evidence) 1, 3
Critical Distinctions
Why Long-Acting Matters:
Avoid short-acting or immediate-release formulations - particularly immediate-release nifedipine, which is contraindicated in hypertension management except with concomitant beta-blockade 5. Short-acting agents cause reflex sympathetic activation and increased cardiovascular risk 5, 9.
Research demonstrates that amlodipine offers superior cardiovascular protection compared to intermediate-acting dihydropyridines, with intermediate-acting agents showing 26% higher risk of myocardial infarction and 25% higher risk of heart failure 10.
Non-Dihydropyridines - Use With Caution:
Diltiazem and verapamil should be avoided in patients with left ventricular dysfunction or heart failure 5, 11. Exercise caution when combining non-dihydropyridine CCBs with beta-blockers due to increased risk of bradyarrhythmias 1, 11, 2.
Practical Prescribing
Amlodipine is the preferred long-acting CCB based on the most robust clinical trial evidence (ALLHAT, VALUE, ASCOT) 6, 7. Start with 5 mg once daily, titrating to 10 mg as needed.
For patients experiencing peripheral edema (the main side effect), consider:
- Switching to lercanidipine (lower edema incidence) 7, 8
- Adding an ACE inhibitor or ARB to reduce edema 7
The WHO 2022 guidelines reinforce that long-acting dihydropyridine CCBs are among the four recommended first-line drug classes with strong recommendation and high-quality evidence 4.